| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is an independent
body and is responsible for the methods it uses in developing its guidance. While
NICE is currently undertaking a review of its methods for health technology evaluation,
the review is not considering combination treatments as a specific topic.</p><p>Commercial
and policy-related challenges for combination treatments are being explored in other
projects in line with the commitments in the Voluntary Scheme for Branded Medicines
Pricing and Access. As stated in the Scheme, the Department and NHS England and NHS
Improvement will support the Association of the British Pharmaceutical Industry’s
efforts to find solutions to these challenges.</p><p> </p>
|
 |
